Artemis Investment Management LLP Has $34.49 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Artemis Investment Management LLP boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 26.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 176,542 shares of the company’s stock after buying an additional 36,384 shares during the quarter. Artemis Investment Management LLP’s holdings in Zoetis were worth $34,493,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Webster Bank N. A. boosted its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Quarry LP lifted its stake in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Zoetis during the 4th quarter worth about $40,000. LRI Investments LLC acquired a new position in Zoetis in the 1st quarter valued at about $43,000. Finally, Hazlett Burt & Watson Inc. raised its holdings in Zoetis by 60.7% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $187.37 on Wednesday. The firm has a 50 day moving average of $187.41 and a 200-day moving average of $175.64. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $84.89 billion, a PE ratio of 36.10, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the business earned $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. On average, equities research analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.